Testosterone cypionate and alcohol: why the combination is risky
Alcohol is part of everyday life for many people, including men receiving testosterone. Our editorial team explains how alcohol affects testosterone, where their risks overlap and why heavy drinking is particularly dangerous in this context.
Testosterone cypionate in context
Testosterone cypionate is an injectable ester of testosterone with an eight-carbon cyclopentylpropionate side chain. Like other esters, it is released slowly from an oil depot in muscle and converted to free testosterone in the blood. It is widely prescribed in the United States for male hypogonadism; in the UK, testosterone replacement is more commonly given as gels, testosterone undecanoate or mixed esters, and cypionate is not among the commonly licensed products.
Medical testosterone therapy aims to restore levels to the normal range in men with confirmed deficiency, as set out in the Endocrine Society guideline by Bhasin and colleagues. Outside medicine, testosterone esters are also used non-medically at higher-than-physiological levels, which changes the risk profile substantially.
Alcohol is the most widely used drug in Britain, so the question of combining it with testosterone arises frequently – from men on prescribed therapy who want to know whether a drink is acceptable, to people using testosterone without supervision who drink heavily.
This article looks at how the two interact physiologically, which organs carry the combined burden and why the combination can be more dangerous than either alone.
How alcohol affects testosterone
Alcohol has well-documented effects on the male reproductive system. A review by Emanuele and Emanuele explained that heavy drinking suppresses testosterone production in the testes, disrupts signalling from the hypothalamus and pituitary, and increases the conversion of androgens to oestrogens through aromatase, especially when liver function is impaired.
For men on prescribed replacement, this means heavy drinking can blunt the benefits of treatment and worsen symptoms such as fatigue, low libido and erectile dysfunction. Alcohol also impairs sleep quality, and poor sleep further reduces energy and wellbeing.
Moderate drinking within UK guidance is generally compatible with testosterone therapy, but this should be discussed with the prescribing doctor. The UK Chief Medical Officers advise that men and women should not regularly drink more than 14 units per week, spread over three or more days, with several alcohol-free days.
Where the risks add up
Both testosterone and alcohol affect the heart, blood, liver and brain. When used together, especially at higher levels, these effects can compound.
| System | Testosterone effect | Alcohol effect | Combined concern |
|---|---|---|---|
| Heart and vessels | Raised blood pressure, lower HDL at high levels | Hypertension, arrhythmias, cardiomyopathy | Greater cardiovascular strain |
| Blood | Increased haematocrit | Dehydration, haemoconcentration | Thicker blood, clot risk |
| Brain and behaviour | Irritability, impulsivity at high levels | Disinhibition, depression | Aggression, risky behaviour |
| Liver | Injectables less hepatotoxic than oral steroids | Fatty liver, hepatitis, cirrhosis | Additive burden with oral agents |
| Sleep | May worsen sleep apnoea | Relaxes airway muscles | Worse nocturnal breathing |
Cardiovascular risk is the most serious overlap. Baggish and colleagues showed in 2017 that long-term non-medical anabolic steroid users had reduced heart pumping function and more coronary plaque than non-users. Heavy alcohol use independently causes high blood pressure, atrial fibrillation – sometimes called "holiday heart" after binge drinking – and alcoholic cardiomyopathy.
Haematocrit is another concern. Testosterone stimulates red blood cell production, which is why monitoring is mandatory during treatment. Binge drinking can cause dehydration, and the combination may thicken the blood further, which increases clot risk.
Behaviour and mental health
Alcohol lowers inhibitions and impairs judgement. At supraphysiological levels, testosterone is associated in some individuals with irritability and impulsivity. The Endocrine Society statement by Pope and colleagues noted associations between non-medical use of anabolic steroids and aggression, violence and polysubstance use.
Kanayama and co-workers described anabolic steroid dependence as a recognised disorder, often accompanied by other substance use. Alcohol is frequently part of this pattern. Depression, which can occur after stopping non-medical steroid use, is also worsened by heavy drinking, and the combination raises the risk of self-harm.
- Increased risk of aggressive or violent incidents
- Risky sexual behaviour and injection practices
- Worsening of depression and anxiety
- Greater likelihood of using other drugs
Practical guidance for people on prescribed therapy
Men receiving medically supervised testosterone should be honest with their doctor about alcohol intake. It affects the interpretation of blood tests, including liver function and haematocrit, and may change treatment decisions.
Staying within UK low-risk drinking guidelines, avoiding binge drinking, staying hydrated and attending scheduled monitoring all reduce risk. Anyone experiencing mood changes, chest pain, palpitations, breathlessness or leg swelling should seek medical help promptly.
People using testosterone without medical supervision face greater risks, and adding heavy alcohol use amplifies them. NHS services and harm-reduction programmes can offer confidential health checks, blood tests and support without judgement.
Editorial team's conclusions
Alcohol lowers testosterone production, increases its conversion to oestrogen and can undermine the benefits of prescribed therapy.
The combination of testosterone, particularly at high levels, and heavy drinking increases the strain on the heart and blood, worsens mental health risks and raises the likelihood of risky behaviour.
For people on medical treatment, moderation within UK guidelines and open communication with the prescriber are the key safeguards.
Related articles on our site cover haematocrit monitoring during testosterone therapy, alcohol and muscle recovery, and sleep apnoea in strength athletes.
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Emanuele MA, Emanuele NV. Alcohol's effects on male reproduction. Alcohol Health Res World. 1998;22(3):195–201.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
- Kanayama G, Brower KJ, Wood RI, et al. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966–1978.
- Department of Health. UK Chief Medical Officers' Low Risk Drinking Guidelines. London: Department of Health; 2016.
